Anixa Biosciences administers second CAR-T dose in ovarian cancer trial [Yahoo! Finance]
Anixa Biosciences, Inc. (ANIX)
Last anixa biosciences, inc. earnings: 3/9 05:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
T-cell (CAR-T) therapy to a patient in a Phase I clinical trial for ovarian cancer. This development follows the patient's positive response to the initial treatment. The trial is being conducted in partnership with Moffitt Cancer Center. Anixa and Moffitt were previously granted approval for a single-patient investigational new drug (IND) application, which permitted the administration of a second dose to the patient. This decision was based on a tumour biopsy that showed cellular infiltration and necrosis, suggesting biological activity of the CAR-T therapy. The patient's condition remained stable after the first infusion, with no need for alternative treatments, and she experienced a good quality of life. These outcomes led to the decision to administer a second dose to further enhance the positive results. Oncologist Dr Monica Avila said: "My patient received her first infusion in May 2023. We are now nearly 18 months from that date, and she is doing well and is now rece
Show less
Read more
Impact Snapshot
Event Time:
ANIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIX alerts
High impacting Anixa Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ANIX
News
- Anixa Biosciences, Inc. (NASDAQ: ANIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical TrialPR Newswire
- Breast cancer vaccine update from Cleveland Clinic: ‘A new era' [FOX News]FOX News
- Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingPR Newswire
ANIX
Earnings
- 9/6/24 - Beat
ANIX
Sec Filings
- 11/8/24 - Form 8-K
- 10/23/24 - Form 4
- 9/6/24 - Form 10-Q
- ANIX's page on the SEC website